Light Chain (AL) Amyloidosis: The Journey to Diagnosis

Kristen L. McCausland (), Michelle K. White, Spencer D. Guthrie, Tiffany Quock, Muriel Finkel, Isabelle Lousada and Martha S. Bayliss
Additional contact information
Kristen L. McCausland: OptumInsight Life Sciences, Inc.
Michelle K. White: OptumInsight Life Sciences, Inc.
Spencer D. Guthrie: Prothena Biosciences Inc
Tiffany Quock: Prothena Biosciences Inc
Muriel Finkel: Amyloidosis Support Groups Inc
Isabelle Lousada: Amyloidosis Research Consortium
Martha S. Bayliss: OptumInsight Life Sciences, Inc.

The Patient: Patient-Centered Outcomes Research, 2018, vol. 11, issue 2, No 7, 207-216

Abstract: Abstract Background Light chain (AL) amyloidosis is a rare, complex disease associated with significant morbidity and mortality. Delays in diagnosis are common and may have detrimental consequences on patients’ prognosis. Too little is known regarding the patient journey to diagnosis. Objective The objective of this study was to describe the patient-reported journey to a correct diagnosis for AL amyloidosis. Methods Using a mixed-methods approach, data were collected from clinician (n = 4) and patient (n = 10) interviews and a survey of community-based patients with AL amyloidosis (n = 341). Data were used to document the patient experience between the onset of symptoms and the receipt of a diagnosis. Results Delays in diagnosis were common. Qualitative and quantitative data indicated that initial symptoms were varied and similar to other more prevalent diseases. Two themes regarding the journey to diagnosis emerged: (1) barriers to an early diagnosis; and (2) the emotional toll of the journey. Time to diagnosis was heavily influenced by how patients interpreted their initial symptoms, whether they sought early medical help, and challenges associated with making differential diagnoses. Survey results indicate that patients with primary cardiac involvement were more likely to receive a delayed diagnosis than those with primary kidney involvement. Patients described mixed emotions associated with the eventual diagnosis of AL amyloidosis. Conclusions These data support a need for better early identification and support for patients seeking a diagnosis. Increasing clinician awareness may reduce the time to diagnosis. Additional research is needed to identify optimal diagnostic testing to reduce delays in treatment initiation and subsequent severe impacts on health.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-017-0273-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:11:y:2018:i:2:d:10.1007_s40271-017-0273-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-017-0273-5

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().